In BRAF/MEK inhibitor-resistant melanoma cells, the secretome held significantly higher amounts of the body's own thymosin beta‑4 than in non-resistant control cells.
In plain wordsIn lab-grown melanoma cells resistant to treatment, the cells released more of their own thymosin beta‑4 than non-resistant cells.
- Peptide
- Thymosin beta-4 (human)
- Outcome
- IncreaseSecreted thymosin beta-4 in resistant melanoma cells
- Study
n: not reported in source
BRAF/MEK inhibitor-resistant melanoma cell secretome- Comparator
- Non-resistant melanoma cells
- Outcome group
- Tumor growth · Cancer
Source sentences
Among the proteins secreted in significantly higher amounts by resistant cells (compared to the control group), which may be potential biomarkers or therapeutic targets in melanoma, plasminogen activator inhibitor 1, thymosin beta-4, clusterin, interleukin-6, superoxide dismutase, and selected matrix metalloproteinases can be distinguished.
1 context sentence(design, population, supporting numbers)
Therefore, this study aimed to examine the protein composition of the secretome of cells resistant to vemurafenib (a BRAF inhibitor) and cobimetinib (a MEK inhibitor) and to compare it with that of nonresistant cells.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.